Navigation Links
Romark Laboratories Awarded Contract For Late-Stage Development Of New Influenza Drug
Date:2/28/2013

TAMPA, Fla., Feb. 28, 2013 /PRNewswire/ -- Romark Laboratories has been awarded a contract with the U.S. Department of Health and Human Services (HHS) to complete the advanced development of NT-300 (nitazoxanide) as a treatment of acute uncomplicated influenza. The value of the cost plus fixed-fee contract is up to $44 million.

(Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO

The contract will be administered through the Biomedical Advanced Research and Development Authority (BARDA).  BARDA, an agency within the Office of the Assistant Secretary for Preparedness and Response, supports advanced development of and procures medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. 

"There is a pressing need for new drugs to treat influenza," said Jean-Francois Rossignol , M.D., Ph.D., Chairman and Chief Science Officer of Romark.  "BARDA plays an important role in the advanced development of new countermeasures for public health threats such as pandemic influenza, and we are pleased to have the opportunity to work with them."

The contract award followed BARDA's solicitation of proposals for development of antiviral therapeutics with new mechanisms of action against influenza. Areas of interest to BARDA addressed by Romark's development plan include a novel mechanism of action, targeting of host factors, potential for broad spectrum antiviral activity and combination therapeutic approaches using an influenza antiviral and a host modulating therapeutic. Importantly, NT-300 is administered orally, and it is being proposed for treatment of seasonal as well as pandemic influenza.

Currently, there are only two c
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Immunotech Laboratories Receives $2M Funding Approval To Begin European Clinical Trials Testing For Companys Patented "IPF" HIV-AIDS Medicines
2. Breaking News: Video Interview With Harry Zhabilov of Immunotech Laboratories Inc.
3. Immunotech Laboratories Appoints New Chief Financial Advisor to Strengthen Companys Growth and International Expansion Plan
4. Dr. Oz, Host Of The Dr. Oz Show, and Harry Zhabilov Of Immunotech Laboratories Discuss Immunotherapy Treatments For Cancer, HIV/AIDS
5. Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures
6. Immunotech Laboratories Announces LOI With International Bio-Tech Partner For USA Clinical Trials Funding Of Patented HIV Medicines
7. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
8. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
9. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
10. Heraeus Named "Supplier of the Year" by National Association of Dental Laboratories
11. New Jensen Dental White Paper Reveals How Dental Laboratories Can Increase Productivity, Profitability with a Multi-Function Pressing Furnace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... report is available in its catalogue: ... U.S. IVD Industry http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... Care Act" (H.R. 3590) is complex legislation that ... many of its provisions are beginning to take ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportbuyer.com has added ... Defibrillators Industry https://www.reportbuyer.com/product/98394/Global-Cardiac-Defibrillators-Industry.html ... in US$ Million by the following Product Segments: Implantable/Internal ... comprehensive analytics for the US, Canada ... , Asia-Pacific , ...
(Date:8/20/2014)... , August 20, 2014 ... market report titled "Monochloroacetic Acid (MCA) Market for Cellulosics, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... valued at USD 817.1 million in 2013 and is ... at a CAGR of 3.6% during the forecast period ...
Breaking Medicine Technology:The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Cardiac Defibrillators Industry 2Global Cardiac Defibrillators Industry 3Global Cardiac Defibrillators Industry 4Global Cardiac Defibrillators Industry 5Global Cardiac Defibrillators Industry 6Global Cardiac Defibrillators Industry 7Global Cardiac Defibrillators Industry 8Global Cardiac Defibrillators Industry 9Global Cardiac Defibrillators Industry 10Global Cardiac Defibrillators Industry 11Global Cardiac Defibrillators Industry 12Global Cardiac Defibrillators Industry 13Global Cardiac Defibrillators Industry 14Global Cardiac Defibrillators Industry 15Global Cardiac Defibrillators Industry 16Global Cardiac Defibrillators Industry 17Global Cardiac Defibrillators Industry 18Global Cardiac Defibrillators Industry 19Global Cardiac Defibrillators Industry 20Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 3Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 4
... July 30 Peptimmune, Inc. a privately,held ... US Patent Number,7,381,790 (the ,790 patent) which ... peptide copolymer for the treatment of autoimmune ... Phase Ib multiple-ascending dose,double-blind, placebo-controlled randomized study ...
... issues a review of,Generex Biotechnology Corporation (Nasdaq: ... Platform, Sets the Tone as Best in,Class Followed ... This review is available at website: http://www.scimitarequity.com ... development, and commercialization,of drug delivery systems and technologies. ...
Cached Medicine Technology:Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis 2Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis 3Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC 2
(Date:8/20/2014)... Loss of brain cells that act as a "sleep ... falling and staying asleep, a new study suggests. ... and often results in nighttime confusion and wandering, according ... the Rush Memory and Aging Project, which includes nearly ... being followed until death, at which point their brains ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... been an option, but a new study shows that only ... common reasons women didn,t undergo reconstruction was that they felt ... they were focused on their cancer treatment," said lead researcher ... Kettering Cancer Center, in New York City. Also common ...
(Date:8/20/2014)... one of the most persistent and deadliest infectious diseases ... each year. , Scientists who study tuberculosis have long ... spread from humans in Africa to seals and sea ... transmitted it to Native people there before Europeans landed ... Reveal Seals as a Source of New World Human ...
(Date:8/20/2014)... Salt Lake City, Utah (PRWEB) August 20, 2014 ... the Inc. 500’s 2014 list of the nation’s fastest growing ... overall growth in the health care sector. Connexion Point is ... specializes in contact centers in Medicare and Medicaid, and its ... in the nation. Connexion Point employs 1,000 people and has ...
(Date:8/20/2014)... YORK, NY (August 20, 2014) Research from Columbia ... critical role in stomach cancer growth and that blocking ... an effective treatment for the disease. The study was ... in collaboration with Duan Chen, MD, PhD, in Norway ... Translational Medicine . , "Scientists have long observed that ...
Breaking Medicine News(10 mins):Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... (Nasdaq: CYNO ), a leading developer and ... systems, today announced financial results for the three and ... Results Consistent with Cynosure,s January 15, 2009 announcement, ... were $25.5 million, reflecting the effect of deteriorating global ...
... Feb. 10 Novasys Medical, Inc., a developer of ... one of the nation,s leading health insurers with over ... treatment for stress urinary incontinence (SUI) in non-pregnant women ... undergo surgery for their condition. According to Aetna,s updated ...
... Kit Offers Extensive Enrollment Information and Insights into ... Feb. 10 HealthLeaders-InterStudy , a leading ... District Survival Kit designed to provide pharmaceutical sales ... and analysis that drives innovative sales strategy development.Each ...
... quarter decline in procedure volume rate shows signs of ... 48% Provides near-term financial outlook CINCINNATI, Feb. 10 ... LCAV ), a leading provider of laser vision correction ... financial and operating results for the three and 12 ...
... OSF HealthCare and Seattle Children,s Hospital among the ... software suiteCLEVELAND, Feb. 10 Healthcare organizations ... healthy lifestyle. Now, hospitals and health systems are ... preaching. Paper medical records cause costly errors, potentially ...
... AHPI ) reported that its net income for ... or zero cents per share in the,prior year period, to ... per,share, primarily because of lower sales volume in the current ... the second quarter fell about 8 percent, or almost $1.1,million, ...
Cached Medicine News:Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 2Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 3Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 4Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 5Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 6Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 7Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 8Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 9Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 10Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 11Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 12Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 13Health News:Aetna Now Covers Novasys Medical's Renessa(R) Treatment for Incontinence in Women 2Health News:HealthLeaders-InterStudy Offers District Survival Kit to Arm Pharmaceutical Sales Teams With Local-Level Managed Care Market Intelligence 2Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 2Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 3Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 4Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 5Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 6Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 7Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 8Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 9Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 10Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 11Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 12Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 13Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 14Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 15Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 16Health News:OnBase is the Choice for a Growing Number of Healthcare Organizations 2Health News:OnBase is the Choice for a Growing Number of Healthcare Organizations 3Health News:Allied Healthcare Reports Second Quarter Loss 2Health News:Allied Healthcare Reports Second Quarter Loss 3Health News:Allied Healthcare Reports Second Quarter Loss 4Health News:Allied Healthcare Reports Second Quarter Loss 5
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
Medicine Products: